Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer
NCT ID: NCT05797831
Last Updated: 2024-05-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2/PHASE3
268 participants
INTERVENTIONAL
2023-07-17
2027-07-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study will be conducted in 2 parts. Part 1 will evaluate safety and efficacy of two different doses of navtemadlin alongside an observational control arm to determine the Phase 3 navtemadlin dose. Part 2 will evaluate the efficacy and safety of navtemadlin Phase 3 dose compared to placebo.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Trametinib With or Without GSK2141795 in Treating Patients With Recurrent or Persistent Endometrial Cancer
NCT01935973
Aminopterin in Treating Patients With Recurrent or Refractory Endometrial Cancer
NCT00003821
Gemcitabine in Treating Patients With Recurrent or Refractory Cancer of the Uterus
NCT00003316
Sacituzumab Tirumotecan (MK-2870) in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
NCT06132958
Cabozantinib S-Malate in Treating Patients With Recurrent or Metastatic Endometrial Cancer
NCT01935934
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part 1 Arm 1
Navtemadlin administered orally at 180 mg, once daily (QD) on Days 1-7 in a 28-day treatment cycles.
Navtemadlin
Navtemadlin is an experimental MDM2 anticancer drug taken by mouth
Part 1 Arm 2
Navtemadlin administered orally at 240 mg, once daily (QD) on Days 1-7 in a 28-day treatment cycles.
Navtemadlin
Navtemadlin is an experimental MDM2 anticancer drug taken by mouth
Part 1 Arm 3
Observational control ("watch and wait") on a 28-day cycle.
No interventions assigned to this group
Part 2 Arm A
Navtemadlin administered orally at 180 mg once daily (QD) on Days 1-7 in a 28-day treatment cycles.
Navtemadlin
Navtemadlin is an experimental MDM2 anticancer drug taken by mouth
Part 2 Arm B
Navtemadlin administered orally at 240 mg once daily (QD) on Days 1-7 in a 28-day treatment cycles.
Navtemadlin
Navtemadlin is an experimental MDM2 anticancer drug taken by mouth
Part 2 Arm C
Placebo administered orally at 180 mg once daily (QD) on Days 1-7 in a 28-day administration cycle.
Navtemadlin Placebo
Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth
Part 2 Arm D
Placebo administered orally at 240 mg once daily (QD) on Days 1-7 in a 28-day administration cycle.
Navtemadlin Placebo
Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Navtemadlin
Navtemadlin is an experimental MDM2 anticancer drug taken by mouth
Navtemadlin Placebo
Navtemadlin placebo is a placebo that is the same in appearance to navtemadlin drug taken by mouth
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Histologically or cytologically confirmed diagnosis of endometrial cancer documented as TP53WT
* Subjects with advanced or recurrent disease must have completed a single line of up to 6 cycles of taxane-platinum based chemo and achieved a CR or PR per RECIST V1.1
* Adequate hematologic, hepatic and renal function (within 14 days)
Exclusion Criteria
* Prior immune therapy, cytokine therapy, or any investigational therapy (within 28 days)
* Indwelling surgical drains
* Grade 2 or higher QTc prolongation
* History of major organ transplant
* History of bleeding diathesis; major hemorrhage or intracranial hemorrhage (within 24 weeks)
18 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GOG Foundation
NETWORK
European Network of Gynaecological Oncological Trial Groups (ENGOT)
OTHER
Kartos Therapeutics, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Kaiser Permanente Center
Vallejo, California, United States
Northside Hospital
Atlanta, Georgia, United States
St. Joseph
Savannah, Georgia, United States
Dr. Sudarshan K. Sharma, Ltd.
Hinsdale, Illinois, United States
Parkview Research Center
Fort Wayne, Indiana, United States
Indiana University
Indianapolis, Indiana, United States
Maryland Oncology Hematology, P.A.
Silver Spring, Maryland, United States
Minnesota Oncology Hematology, P.A.
Minneapolis, Minnesota, United States
Washington University School of Medicine
St Louis, Missouri, United States
Women's Cancer Center of Nevada
Las Vegas, Nevada, United States
Good Samaritan Hospital Medical Center
West Islip, New York, United States
FirstHealth Carolinas
Pinehurst, North Carolina, United States
OhioHealth Institute
Columbus, Ohio, United States
Oklahoma Cancer Specialists and Research Institute
Tulsa, Oklahoma, United States
Oncology Associates of Oregon
Eugene, Oregon, United States
Northwest Cancer Specialists
Portland, Oregon, United States
Texas Oncology-Austin Central
Austin, Texas, United States
Texas Oncology-Fort Worth Cancer Center
Fort Worth, Texas, United States
Texas Oncology-San Antonio Medical Center
San Antonio, Texas, United States
University Hospital Graz, Department of Gynecology and Obstetrics
Graz, , Austria
Medizinische Universität Innsbruck
Innsbruck, , Austria
Medizinische Universität Wien
Vienna, , Austria
Cross Cancer Institute
Edmonton, , Canada
CHUM - University of Montreal Hospital Centre
Montreal, , Canada
Odense University Hospital
Odense, , Denmark
Tartu University Hospital
Tartu, , Estonia
Kuopio University Hospital
Kuopio, , Finland
Turku University Hospital
Turku, , Finland
LTD High Technology hospital Medcenter
Batumi, , Georgia
American Hospital Network LLC
Tbilisi, , Georgia
Caucasus Medical Centre
Tbilisi, , Georgia
National Institute of Oncology
Budapest, , Hungary
University of Debrecen Clinical Center
Debrecen, , Hungary
Rambam Medical Center
Haifa, , Israel
Shaare Zedek Medical Center
Jerusalem, , Israel
Sourasky Medical Center
Tel Aviv, , Israel
A.O. Cannizzaro
Catania, , Italy
IRCCS Istituto Romangolo per lo Studio dei Tumori "Dino Amadori"
Forlì, , Italy
Ospedale Policlinico San Martino
Genoa, , Italy
ASST di Lecco-Ospedale Alessandro Manzoni
Lecco, , Italy
Ospedale San Luca
Lucca, , Italy
Osp. Niguarda
Milan, , Italy
University Hospital of Parma
Parma, , Italy
Ospedale Guglielmo da Saliceto
Piacenza, , Italy
Ospedale di Prato S. Stefano
Prato, , Italy
Ospedale Santa Maria delle Croci
Ravenna, , Italy
"Azienda Unità Sanitaria Locale della Romagna - Hospital ""Infermi"" of Rimini Oncology Department"
Rimini, , Italy
Policlinico Umberto
Rome, , Italy
Ospedale Filippo Del Ponte
Varese, , Italy
Health Sciences Kaunas Clinics
Kaunas, , Lithuania
Nation Cancer Institute of Lithuania, Vilnius
Vilnius, , Lithuania
Southern Hospital Sorlandet
Kristiansand, , Norway
Oslo University Hospital HF
Oslo, , Norway
Sykehusapotek Nord Tromsø
Tromsø, , Norway
Białostockie Centrum Onkologii
Bialystok, , Poland
Szpitale Pomorskie
Gdansk, , Poland
Uniwersyteckie Centrum Kliniczne
Gdansk, , Poland
NIO-PIB Oddzial w Gliwicach
Gliwice, , Poland
Centrum Badań klinicznych Jagiellońskie Centrum Innowacji
Krakow, , Poland
Siedleckie Centrum Onkologii
Olsztyn, , Poland
Uniwersytecki Szpital
Poznan, , Poland
NIO-PIB Klinika Gine-Onk
Warsaw, , Poland
Lower Silesian Oncology, Pulmonology and Hematology Center, Department of Oncological Gynecology
Wroclaw, , Poland
Bucharest CF2 Hospital
Bucharest, , Romania
Ovidius Clinical Hospital SRL
Constanța, , Romania
Onco Clinic Consult S.A.
Craiova, , Romania
Oncology Center "Sf. Nectarie"
Craiova, , Romania
Gral Medical S.R.L. - Oncofort Hospital
Piteşti, , Romania
Oncocenter, Oncology Clinic SRL
Timișoara, , Romania
SC Oncomed SRL
Timișoara, , Romania
Institute of Oncology Ljubljana
Ljubljana, , Slovenia
University Clinical Center Maribor
Maribor, , Slovenia
CHUAC (Hospital de Coruña)
A Coruña, , Spain
Hospital del Mar
Barcelona, , Spain
Hospital Galdakao-Usansolo
Galdakao, , Spain
Hospital Universitario de Jaen
Jaén, , Spain
H.G.U. Jerez de la Frontera
Jerez de la Frontera, , Spain
Hospital U Insular de GC
Las Palmas, , Spain
Hospital de Leon
León, , Spain
HCU Santiago de Compostela
Santiago de Compostela, , Spain
Hospital Universitario de Valme
Seville, , Spain
Linkoping University Hospital
Linköping, , Sweden
Karolinska University Hospital
Stockholm, , Sweden
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ENGOT en-21
Identifier Type: OTHER
Identifier Source: secondary_id
GOG-3089
Identifier Type: OTHER
Identifier Source: secondary_id
KRT-232-118
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.